contentSlug

type

ContentSlug_ContentQuery

slug

ContentPageContentQuery

content

trendingContent

query ContentSlug_ContentQuery(
  $contentSlug: String!
  $type: [ContentType!]
) {
  ...ContentPageContentQuery_13QmVO
}

fragment CompanyDetails_Content on Content {
  __isContent: __typename
  companies {
    name
    description
    pageUrl
    id
  }
}

fragment ContentBasicInfo on Content {
  __isContent: __typename
  id
  type
  title
  lang
  companies {
    viewerIsFollowing
    id
    name
    pageUrl
  }
  tags {
    viewerIsFollowing
    id
    name
    pageUrl
  }
  ...PublishingDetails
  ...Reactions
}

fragment ContentMetadata on Content {
  __isContent: __typename
  type
  title
  lang
  pageUrl
  alternatePageUrls: translations {
    __typename
    pageUrl
    lang
  }
  imgUrl
  description
  ... on Video {
    liveTime
    videoUrl
  }
  ... on Webcast {
    liveTime
    videoUrl
  }
}

fragment ContentPageContentQuery_13QmVO on Query {
  content(slug: $contentSlug, type: $type) {
    __typename
    id
    type
    title
    isPremium
    lang
    htmlBody
    summary
    companies {
      forum {
        latestPosts {
          ...ForumPosts
        }
      }
      name
      id
      viewerIsFollowing
      pageUrl
      defaultInstrument {
        isin
        id
        marketOpen
        marketClose
        marketplace {
          region
        }
        returns {
          total
        }
      }
    }
    tags {
      viewerIsFollowing
      id
      name
      pageUrl
    }
    createdAt
    ... on Video {
      liveTime
    }
    ... on Webcast {
      liveTime
    }
    slug
    ... on CompanyReport {
      reportUrl
      researchContentUrl
    }
    ... on ThirdPartyCompanyReport {
      reportUrl
    }
    ... on StockExchangeRelease {
      reportUrl
    }
    ...ContentBasicInfo
    ...ContentMetadata
    ...PriceAndRecommendation_Content
    ...CompanyDetails_Content
    ...ReportLink_Content
    ...KeyFigures_Content
  }
  ...TrendingContent_1jQ2Cn
}

fragment ForumPosts on ForumPost {
  text
  likesCount
  url
  author
  postedAt
  authorImgUrl
}

fragment KeyFigures_Content on Content {
  __isContent: __typename
  companies {
    defaultInstrument {
      estimateData {
        modelType
        reportingCurrency
      }
      snapshot {
        transaction {
          date
          actualized {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
            nav
            navPerShare
            opexOfNav
            quarterlySharePrice
          }
          estimates {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
            nav
            navPerShare
            opexOfNav
            quarterlySharePrice
          }
        }
      }
      id
    }
    id
  }
}

fragment PriceAndRecommendation_Content on Content {
  __isContent: __typename
  createdAt
  companies {
    name
    pageUrl
    defaultInstrument {
      priceData {
        tradeCurrency
      }
      snapshot {
        priceData {
          date
          lastPrice
          tradeCurrency
        }
        transaction {
          date
          recommendation
          targetPrice
        }
        prevTransaction {
          recommendation
        }
      }
      id
    }
    id
  }
}

fragment PublishingDetails on Content {
  __isContent: __typename
  createdAt
  publishers {
    name
    imgUrl
  }
  authors {
    __typename
    id
    name
    slug
    imgUrl
    jobTitle
  }
  ... on Video {
    liveTime
  }
  ... on Webcast {
    liveTime
  }
}

fragment Reactions on Content {
  __isContent: __typename
  id
  reactionGroups {
    reactionType
    reactionsCount
    viewerReacted
  }
}

fragment ReportLink_Content on Content {
  __isContent: __typename
  type
  isPremium
  ... on CompanyReport {
    reportUrl
  }
  ... on ThirdPartyCompanyReport {
    reportUrl
  }
  ... on StockExchangeRelease {
    reportUrl
  }
}

fragment TrendingContent_1jQ2Cn on Query {
  trendingContent(type: ARTICLE) {
    __typename
    id
    title
    lang
    pageUrl
    createdAt
    type
    imgUrl
    companies {
      squareLogoUrl
      name
      id
    }
    authors {
      __typename
      imgUrl
      id
    }
    publishers {
      imgUrl
    }
  }
}


annexin-pharmaceuticals-publicerar-arsredovisningen-for-2025

__typename

title

isPremium

lang

htmlBody

summary

companies

createdAt

publishers

authors

reactionGroups

pageUrl

translations

imgUrl

description

Annexin Pharmaceuticals is a biotechnology company developing the drug candidate ANXV, based on the protein Annexin A5, for the treatment of diseases such as vascular damage, inflammation and certain cancers. The company's partners are healthcare providers and biopharmaceutical companies and the business is aimed at global markets through research and licensing collaborations. The company was founded in 2014 and is headquartered in Stockholm, Sweden.

Annexin Pharmaceuticals

Annexin Pharmaceuticals publicerar idag den fullständiga årsredovisningen för 2025 på www.annexinpharma.se.Annexins årsstämma hålls tisdagen den 12 maj 2026.Rapporten kan nås på bolagets hemsida...

<div class="mfn-preamble"><p><strong>Annexin Pharmaceuticals publicerar idag den fullständiga årsredovisningen för 2025 på </strong><strong><a href="https://annexinpharma.se/investerare/financial-reports/" rel="noopener">www.annexinpharma.se</a></strong><strong>.</strong></p></div><div class="mfn-body"><p>Annexins årsstämma hålls tisdagen den 12 maj 2026.</p><p><em>Rapporten kan nås på bolagets hemsida via nedanstående länk:</em><br><a href="https://annexinpharma.se/investerare/financial-reports/" rel="noopener">Annexinpharma årsredovisning 2025</a></p><p>För mer information, vänligen kontakta:<br>Anders Haegerstrand, VD<br>Tfn: +46 (0)70 575 50 37<br>Mail:&nbsp;<a href="mailto:anders.haegerstrand@annexinpharma.com" rel="noopener">anders.haegerstrand@annexinpharma.com</a></p><p>Susanne Andersson, CFO<br>Tfn: +46 (0)730&nbsp;668 904<br>Mail:&nbsp;<a href="mailto:susanne.andersson@annexinpharma.com" rel="noopener">susanne.andersson@annexinpharma.com</a></p><p><em>Informationen lämnades, genom ovanstående kontaktpersoners försorg, för offentliggörande den 26 mars 2026 kl. 08:30 CET.</em></p></div><div class="mfn-footer mfn-about mfn-d80162962aba"><p><strong class="mfn-heading-1">Om Annexin Pharmaceuticals AB (publ)</strong><br>Annexin Pharmaceuticals är ett bioteknikföretag i klinisk fas med verksamhet inom de terapeutiska områdena oftalmologi och onkologi. Företaget utvecklar ANXV, ett rekombinant humant Annexin A5-protein, som ett first-in-class biologiskt läkemedel med potentiellt sjukdomsmodifierande verkningsmekanismer. ANXV-programmet befinner sig för närvarande i fas 2 inom oftalmologi för retinal venocklusion (RVO) och diabetesretinopati (DR), samt i preklinisk fas inom onkologi.<br>Bolaget är baserat i Stockholm och noterat på Nasdaq First North Growth Market under kortnamnet ANNX. Redeye Nordic Growth&nbsp; AB är företagets certifierade rådgivare.</p></div><div class="mfn-footer mfn-attachment mfn-attachment-general"><p><strong class="mfn-heading-1">Bifogade filer</strong><br><a class="mfn-primary" href="https://storage.mfn.se/60beeeaf-72cd-4f1e-b8f6-0c3e5c07d76b/annexin-arsredovisning-2025-final.pdf" rel="noopener">Annexin Årsredovisning 2025 Final</a></p></div>